Danaher Co. (NYSE:DHR) Shares Sold by Raymond James Trust N.A.

Raymond James Trust N.A. decreased its position in Danaher Co. (NYSE:DHRGet Rating) by 3.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 17,895 shares of the conglomerate’s stock after selling 559 shares during the period. Raymond James Trust N.A.’s holdings in Danaher were worth $4,536,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. City Holding Co. raised its stake in Danaher by 13.0% in the 1st quarter. City Holding Co. now owns 4,133 shares of the conglomerate’s stock valued at $1,212,000 after purchasing an additional 475 shares during the last quarter. Sawgrass Asset Management LLC acquired a new position in shares of Danaher during the 1st quarter valued at about $14,635,000. O Brien Greene & Co. Inc increased its stake in shares of Danaher by 1.5% during the 1st quarter. O Brien Greene & Co. Inc now owns 37,457 shares of the conglomerate’s stock valued at $10,987,000 after acquiring an additional 562 shares during the last quarter. RDA Financial Network increased its stake in shares of Danaher by 73.4% during the 1st quarter. RDA Financial Network now owns 2,763 shares of the conglomerate’s stock valued at $810,000 after acquiring an additional 1,170 shares during the last quarter. Finally, Selective Wealth Management Inc. grew its holdings in shares of Danaher by 500.0% during the 1st quarter. Selective Wealth Management Inc. now owns 348 shares of the conglomerate’s stock worth $102,000 after purchasing an additional 290 shares during the period. Institutional investors and hedge funds own 77.27% of the company’s stock.

Insider Buying and Selling

In related news, Director Walter G. Lohr sold 3,906 shares of the stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $273.84, for a total value of $1,069,619.04. Following the completion of the sale, the director now directly owns 12,115 shares of the company’s stock, valued at approximately $3,317,571.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Joakim Weidemanis sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, July 25th. The stock was sold at an average price of $271.13, for a total value of $3,253,560.00. Following the transaction, the executive vice president now directly owns 74,398 shares of the company’s stock, valued at approximately $20,171,529.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Walter G. Lohr sold 3,906 shares of the firm’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $273.84, for a total value of $1,069,619.04. Following the completion of the sale, the director now directly owns 12,115 shares in the company, valued at approximately $3,317,571.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,906 shares of company stock valued at $11,823,179. Corporate insiders own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Cowen decreased their price target on Danaher to $340.00 in a report on Friday, July 22nd. Credit Suisse Group assumed coverage on Danaher in a research report on Wednesday, August 24th. They set an “outperform” rating and a $340.00 price target on the stock. StockNews.com raised Danaher from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 26th. Benchmark dropped their price target on Danaher from $345.00 to $325.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Barclays increased their target price on Danaher from $290.00 to $310.00 in a research report on Friday, July 22nd. One research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $321.75.

Danaher Trading Down 0.8 %

NYSE:DHR opened at $266.43 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.75 and a debt-to-equity ratio of 0.45. Danaher Co. has a 1-year low of $233.71 and a 1-year high of $331.68. The firm has a market capitalization of $193.81 billion, a price-to-earnings ratio of 31.38, a price-to-earnings-growth ratio of 1.29 and a beta of 0.88. The stock has a fifty day simple moving average of $280.99 and a 200 day simple moving average of $269.91.

Danaher (NYSE:DHRGet Rating) last released its quarterly earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share for the quarter, beating analysts’ consensus estimates of $2.35 by $0.41. Danaher had a return on equity of 18.57% and a net margin of 20.61%. The business had revenue of $7.75 billion during the quarter, compared to analyst estimates of $7.29 billion. During the same quarter last year, the company posted $2.46 EPS. Danaher’s revenue for the quarter was up 7.4% on a year-over-year basis. Sell-side analysts forecast that Danaher Co. will post 10.4 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 30th will be paid a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 0.38%. The ex-dividend date is Thursday, September 29th. Danaher’s dividend payout ratio is currently 11.78%.

About Danaher

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.